WaveMan
WaveMan · Company
COCH · Envoy Medical, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

COCH Envoy Medical (COCH) Insider Trading, Ownership & Congress Trades

Medical Devices · Orthopedic, prosthetic & surgical appliances & supplies · CIK 0001840877
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
14
13F, latest reported quarter

Envoy Medical insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Envoy Medical, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Patel Mona Chetan
Director
BUY
2026-02-17 SECtraded 2026-02-12
312,500
$125.0K
+758.7%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on Jun 11, 2025.
  • -32.7% median (-24.5% mean) 90-day return after 5 previous buys.
  • The trade is 94.0% of the 332,500 shares held after it.
  • 5 other insiders bought within 30 days.
  • 14 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Patel Mona Chetan bought about $125.0K of COCH on Feb 12, 2026, the largest insider purchase at the company on our record; 5 other insiders bought within 30 days and 14 funds added in the latest 13F quarter.
Potashnick Robert
Interim CFO
BUY
2026-02-17 SECtraded 2026-02-12
212,500
$85.0K
+758.7%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 212,500 shares held after it.
  • 5 other insiders bought within 30 days.
  • 14 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Interim CFO Potashnick Robert bought about $85.0K of COCH on Feb 12, 2026, the largest insider purchase at the company on our record; 5 other insiders bought within 30 days and 14 funds added in the latest 13F quarter.
Kantor Susan
Director
BUY
2026-02-17 SECtraded 2026-02-12
96,150
$38.5K
+758.7%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 55.2% of the 174,037 shares held after it.
  • 5 other insiders bought within 30 days.
  • 14 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Kantor Susan bought about $38.5K of COCH on Feb 12, 2026; 5 other insiders bought within 30 days and 14 funds added in the latest 13F quarter.
BRYNELSEN CHARLES
Director
BUY
2026-02-17 SECtraded 2026-02-12
1,000,000
$400.0K
+758.7%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on May 27, 2025.
  • -27.6% median (-26.5% mean) 90-day return after 3 previous buys.
  • The trade is 95.2% of the 1,050,000 shares held after it.
  • 5 other insiders bought within 30 days.
  • 14 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director BRYNELSEN CHARLES bought about $400.0K of COCH on Feb 12, 2026, the largest insider purchase at the company on our record; 5 other insiders bought within 30 days and 14 funds added in the latest 13F quarter.
Lucas Brent T.
Chief Executive Officer
BUY
2026-02-17 SECtraded 2026-02-12
62,500
$25.0K
+758.7%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Nov 21, 2023.
  • The trade is 21.0% of the 297,090 shares held after it.
  • 5 other insiders bought within 30 days.
  • 14 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Lucas Brent T. bought about $25.0K of COCH on Feb 12, 2026; 5 other insiders bought within 30 days and 14 funds added in the latest 13F quarter.
16 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 11 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
14 funds bought in last quarter
below 78% of Medical Devices
Revenue
+7.1% year over year
below 58% of Medical Devices
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
11.5% of the float short (float per yahoo 2026-10-26) · 8.0 days to cover · settled 2026-09-30
below 76% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch COCH

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+689.8%12M
-53%+219%+490%+761%2025-102025-122026-022026-042026-062026-082026-10 2026-02-12 · TAYLOR GLEN A bought $7.5M2026-02-12 · BRYNELSEN CHARLES bought $400.0K2026-02-12 · Patel Mona Chetan bought $125.0K2026-02-12 · Potashnick Robert bought $85.0K2026-02-12 · Kantor Susan bought $38.5K2026-02-12 · Lucas Brent T. bought $25.0K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns COCH: institutional holders (13F)

13F holdings, latest reported quarter
Nantahala Capital Management, LLC
15,300,000 sh
$11.9M
Bleichroeder LP
6,250,000 sh
$5.0M
VANGUARD CAPITAL MANAGEMENT LLC
880,214 sh
$697.1K
DSG Capital Advisors, LLC
625,000 sh
$474.2K
GEODE CAPITAL MANAGEMENT, LLC
541,729 sh
$429.1K

Congress trades in COCH

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

COCH planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

COCH mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$225.1K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$480.5K position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$27.0K position · as of 2026-05-31
0.0%
Fidelity Series Total Market Index Fund
$45.8K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$26.4K position · as of 2026-05-31
0.0%
Calamos Market Neutral Income Fund
$3.4K position · as of 2026-07-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 14 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

COCH financials

Revenue growth
+7.1%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$207.0K
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
-$21.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
n/a
average equity is zero or negative
Return on assets
-138.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
no debt line filed
Return on capital employed
-357.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-4.3%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$241.0K$225.0K$316.0K$237.0K
Operating income-$22.3M-$19.3M-$18.4M-$8.7M
Net income-$23.8M-$20.8M-$29.9M-$15.9M
EPS (diluted)-1.23-1.49-2.54-1.57
Operating cash flow-$18.2M-$17.9M-$17.1M-$8.8M
Cashn/an/a$4.2M$183.0K
Dividends paid$1.8M$2.4Mn/an/a
SEC XBRL, fiscal years, as known on 2026-10-28

COCH Stock Sonar score 4/7 axes

Find similar shapesCompare

COCH ranks highest on growth (42nd percentile) and risk and compliance (35th), and lowest on profitability (6th), among Medical Devices peers.

Profitability
6
Inputs
  • Return on equityaverage equity is zero or negative
  • Return on assets-138.3% · 11 pct, sector of 214
  • Return on invested capitalno debt line filed
  • Return on capital employed-357.5% · 2 pct, sector of 188
Growth
42
Inputs
  • Revenue growth, YoY+7.1% · 42 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
11
Inputs
  • Funds adding, latest quarter14 · 22 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$20K · 0 pct, sector of 50
Risk and compliance
35
Inputs
  • Short interest, % of float+11.5% · 16 pct, sector of 240
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+9.7% · 55 pct, sector of 198
3 not measured: Financial health, Insider conviction, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies